Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222675 | 1.00 | DPP4 (0.60) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL24491967 | 1.00 | DPP4 (0.60) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL29290578 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL24491945 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL29290591 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL24491997 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL24491836 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL24491991 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL29290580 | 0.91 | DPP4 (0.52) | DPP4HPGDRECQLEPHX1GPR119 | |
| SCHEMBL23826102 | 0.89 | DPP4 (0.62) | DPP4HPGDRECQLEPHX1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7842718-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050196813-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-09-08 | — | — | US | disclosed |
| US-6878742-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH | 2003-12-11 | — | — | US | disclosed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | disclosed |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | DPP4 3190/4885HPGD 1143/4885RECQL 279/4885 |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, PSEN1 | DPP4 3622/4885HPGD 864/4885RECQL 126/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | DPP4 1443/4885HPGD 2354/4885RECQL 3834/4885 |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | DPP4 3622/4885HPGD 864/4885RECQL 126/4885 |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | DPP4 3190/4885HPGD 1143/4885RECQL 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.